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Aim: The purpose of this study was to compare visual outcomes, surgical time, and perioperative
surgical complications after intracameral use of either phenylephrine/ketorolac (P/K) or
epinephrine (Epi) during cataract surgery.
Methods: This was a single-center, retrospective case review of patients undergoing cataract
surgery from August to November 2015. Of the 641 eyes of 389 patients who underwent
cataract surgery, 260 eyes were administered phenylephrine 1.0%/ketorolac 0.3% and 381 eyes
received Epi in the irrigation solution intraoperatively. All patients received a topical nonsteroidal
anti-inflammatory drug regimen (bromfenac 0.07%, nepafenac 0.3%, or ketorolac 0.5%) for
3 days before surgery and topical tropicamide 1.0%, cyclopentolate 1.0%, and phenylephrine
2.5% on the day of surgery.
Results: Mean length of surgery (LOS) was 15.4±0.6 minutes. Although a positive correlation was noted between patient age and LOS (p,0.001), P/K was associated with a decrease
in the LOS, when controlled for age quartiles. A statistically significant lower incidence of
complications (1.1%) was observed with P/K use than Epi (4.5%; p=0.018). Among surgeons
who used mydriatic-assist devices more frequently, P/K use was associated with a reduction in
the use of these devices (p,0.001). When controlling for age quartile, patients of age groups
69–76 and 76–92 years who received P/K had significantly better uncorrected visual acuity at
postoperative day 1 than those receiving Epi (p=0.003).
Conclusion: Intracameral use of phenylephrine 1.0%/ketorolac 0.3% during cataract surgery
may be effective in maintaining mydriasis. It appears to be superior to intracameral Epi at
reducing intraoperative and postoperative complications, need for pupillary dilating devices,
and surgical time.
Keywords: cataract surgery, complications, pupillary miosis, phenylephrine, ketorolac
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Cataract surgery is one of the most frequently performed procedures worldwide.
Age-related cataracts alone are expected to affect more than 30 million Americans
by 2020.1,2 Advancements in cataract surgery techniques, technology, and pharmaceutical therapies have reduced the risks associated with the procedure and improved
outcomes. In recent years, cataract surgery has evolved into an outpatient, relatively
pain-free procedure with rapid recovery of vision. Perhaps as a result, patients now
have very high expectations of cataract surgery, including a low tolerance for complications and pain.3,4
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A small pupil (,6.0 mm) or intraoperative miosis is
known to make cataract surgery more technically challenging
and increase the risk of surgical complications such as
capsular tears, lens decentration, retained lens fragments,
postoperative inflammation, or vitreous loss.5–10 One group
of researchers found a twofold increase in complications with
each 1.0 mm reduction in pupil size.6
There are a variety of therapeutic treatments aimed at
improving pupillary dilation and preventing intraoperative miosis, including several topical agents that have been
approved by the US Food and Drug Administration (FDA) for
ophthalmic use. Preoperative dilation with topical sympatho
mimetics, such as phenylephrine, and anticholinergics, such
as cyclopentolate or tropicamide, have a long track record
of efficacy. Topical nonsteroidal anti-inflammatory drugs
(NSAIDs) can also reduce the severity and incidence of intraoperative miosis by preventing prostaglandin synthesis.11,12
Topical agents administered preoperatively can, however,
be washed out of the intracameral space by the irrigation
solution used during cataract surgery.13 Cardiac sympatho
mimetics such as epinephrine (Epi) or phenylephrine added
to the irrigating solution are effective at preventing miosis
but are not FDA approved for this use and may be subject
to formulation errors and/or contamination.
Recently, an intracameral combination drug (phenylephrine 1.0%/ketorolac 0.3%, Omidria; Omeros, Seattle, WA,
USA) intended to be added to the irrigating solution, was
approved for cataract and intraocular lens replacement
surgery. Containing both an α1-adrenergic receptor agonist and a nonselective cyclooxygenase 1 and 2 inhibitor,
phenylephrine/ketorolac (P/K) combination has been shown
to maintain pupillary mydriasis and reduce postoperative
pain in a Phase III multicenter, randomized study.14
NSAIDs and adrenoceptor agonist agents have a longstanding history of use in the management of ocular pathology
and topical ophthalmic preparations. Although intracameral
ketorolac has not been previously studied during cataract
surgery, intracameral administration would be expected to
have some advantages. Since the intracameral combination
drug is introduced into the operative irrigation solution prior
to the case, it does not require any modification to current
surgical techniques or procedures. Additionally, presenting
the combination therapy intracamerally exposes the target
tissues to a consistent concentration of drug, maintaining the
pharmacological effects.14 Other recognized advantages of
P/K over current techniques include prevention of intraoperative miosis, reduction of pain and discomfort, management
of postoperative inflammation, reduction in the number of
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pre- and postoperative topical drops, and the availability of
a bisulfite-free preparation.8,14,15
In the very limited peer-reviewed literature examining
this combined agent thus far, the drug has not been evaluated in patients with risk factors for intraoperative miosis
such as intraoperative floppy iris syndrome (IFIS) or
pseudoexfoliation.8,14 Additionally, while all subjects in
the FDA trial received standardized topical preoperative
mydriatics (phenylephrine and tropicamide) and anesthetics
(lidocaine or tetracaine), they did not receive intracameral
Epi or a topical NSAID. The purpose of this study was to
evaluate, in a real-world setting, the incidence of perioperative complications, length of surgery (LOS), and use of pupil
dilation devices in a broad patient population, including those
with comorbid conditions that would make surgery more difficult, such as IFIS, pseudoexfoliation, and otherwise poorly
dilating pupils. To reflect common clinical practice, the P/K
treatment group was compared to a control group receiving
intracameral Epi, and all patients in the study received
standard preoperative topical NSAIDs.

Methods
A single-center retrospective case review was performed
for all cataract surgeries taking place at Island Eye Surgical
Center, Carle Place, NY, over a 3-month period from August
2015 to November 2015, plus associated first-eye procedures
as described below. Four surgeons (EDD, GD, JB, and RJL)
were selected as having performed more than five cataract
surgeries per week during the review period, including cases
using intracameral P/K (Omidria) and cases using intra
cameral Epi without P/K. If the cataract surgery performed
between the inclusion dates was a second-eye surgery, that
subject’s first-eye surgery was included in the retrospective
review as well, as long as the first eye underwent surgery after
January 1, 2014. Exclusion criteria were age younger than
21 years, documented sensitivity to NSAIDs, and planned
combined cataract and posterior segment surgeries. All
other procedures performed by the selected surgeons during
the review period were included. The study was conducted
according to the tenets of the Declaration of Helsinki; additionally, this research was exempt from Institutional Review
Board approval under the HHS policy: 45 CFR 46.101(b).
All patients received a topical NSAID regimen (bromfenac 0.07%, nepafanac 0.3%, or ketorolac 0.5%) for 3 days
before surgery. On the day of surgery, all patients received
topical tropicamide 1%, cyclopentolate 1%, and phenylephrine 2.5%. Depending upon the insurance coverage, either
phenylephrine 1%/ketorolac 0.3% or Epi was used in the
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irrigation solution. P/K was stored between 20°C and 25°C
and protected from ambient light at all times prior to use.
Before each P/K case, one 4 mL single-patient-use vial of the
combination drug was added to a 500 mL bottle of irrigation
solution in the surgical suite. Once added to the irrigation
solution, the drug was delivered intracamerally within the
4-hour recommended time frame. In the remaining patients,
1 cc of 1:1,000,000 concentration of bisulfite-free Epi was
added to the irrigation solution.
Each chart was reviewed for surgeon name, date of surgery, age at time of surgery, sex, eye, use of the femtosecond
laser, use of mydriatic-assist devices (Malyugin rings or iris
hooks), use of P/K, history or current use of α1 antagonists,
and perioperative complications. In addition, the charts of
one surgeon (EDD, n=310 eyes) were reviewed for bestcorrected visual acuity (BCVA) and uncorrected visual acuity
(UCVA) preoperatively and at postoperative day 1 (POD 1)
and month 1 (POM 1). All visual acuities were converted
from Snellen to decimal format in order to facilitate calculation and statistical analysis.
Results were analyzed by age quartile. For statistical
analyses, Student’s t-tests, correlation tests, z-score, analysis
of variance (ANOVA), two-way ANOVA, and χ2 tests
were utilized where appropriate. A p-value of ,0.05 was
considered significant. Regression models were fit to adjust
for imbalance in group characteristics, and to assess the
overall impact of independent variables on the outcomes of
interest. Statistical analyses were performed using RStudio

(https://www.r-project.org) and Excel (Microsoft Corporation,
Redmond, WA, USA).

Results
Surgeons EDD, GD, JB, and RJL performed a total of
653 cataract surgery procedures during the review period.
Twelve eyes were excluded based on previously indicated
exclusion criteria. Of the 641 eyes of 389 patients analyzed,
413 were of female patients and 228 male; 323 were right
eyes and 318 were left eyes. Fifty-three eyes had a positive
history for α1 antagonist use. Two hundred seventy-eight eyes
underwent pretreatment with the femtosecond laser. Of the
641 eyes, 260 were administered P/K intraoperatively, while
the remaining 381 had Epi. The average age of a patient
receiving phenylephrine/ketorolac was 75.4±0.9 years, while
the average of a patient receiving Epi was 67.4±1.1 years
(p,0.001). A mydriatic-assist device (Malyugin ring or iris
hooks) was required to maintain mydriasis in 45 eyes.
Overall, the group receiving P/K were older than the
group receiving Epi (Student’s t-test, p,0.0001), and more
patients were female (Student’s t-test, p=0.0016) (Table 1).
When comparing treatment groups across surgeons, the mean
age of the groups receiving either P/K or Epi was significantly
different (χ2, p=0.045 and p,0.0001, respectively), but the
percent of female patients receiving P/K was similar for
all surgeons (χ2, p=0.056). For both treatment groups, the
percent of patients undergoing femtosecond laser was not
significantly different overall (p=0.0980).

Table 1 Characteristics of eligible patients
Surgeon

Treatment

N

Mean age,
years (SD)

Female, %

Eye, %
right

Femtosecond
laser, %

α-blocker, %

Overall

P/K
Epi
p-value

260
381

75.5 (7.2)
67.4 (10.7)
,0.0001

71.5
59.6
0.0016

50.4
51.2
0.8433

47.3
40.7
0.0980

8.1
8.4
0.8843

EDD

P/K
Epi
p-value

141
169

74.7 (7.1)
63.5 (10.8)
,0.0001

68.8
55.6
0.0168

50.4
49.7
0.9096

52.5
54.4
0.7321

6.4
5.9
0.8658

JB

P/K
Epi
p-value
P/K
Epi
p-value
P/K
Epi
p-value

32
59

77.6 (6.3)
71.3 (9.5)
0.0003
75.5 (7.6)
69.7 (10.9)
0.0027
76.8 (7.3)
70.8 (8.2)
,0.0001

87.5
74.6
0.1210
82.1
72.2
0.2691
64.4
43.2
0.0147

53.1
50.8
0.8382
46.4
50.6
0.7076
50.8
52.7
0.8332

21.9
16.9
0.5825
39.3
36.7
0.8136
52.5
32.4
0.0202

6.3
10.2
0.5075
7.1
8.9
0.7724
13.6
12.2
0.8133

P/K
Epi

260
381

0.0451
,0.0001

0.0564
0.0002

0.9644
0.9798

0.0107
,0.0001

0.3924
0.4003

GD

RJL

Comparison
across surgeons

28
79
59
74

Abbreviations: Epi, epinephrine; P/K, phenylephrine/ketorolac; SD, standard deviation.
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The average LOS was 15.4±0.6 minutes, ranging from
13.0±1.0 to 17.2±1.3 (Figure 1A and B). A positive correlation was noted between age and LOS (p,0.001) (Figure 1C).
LOS was not exclusively dependent on sex (Student’s t-test,
p=0.732) or eye (p=0.694), or use of P/K (p=0.676). However,
when controlling for age quartile, the use of P/K was associated with a decrease in the LOS in most of the age quartiles
compared to Epi (oldest quartile, age 78–92: 15.6±1.5 minutes
vs 16.7±1.2 minutes; age 71–77: 16.0±1.8 vs 16.2±1.5; age
65–70: 13.7±1.7 vs 17.2±1.7; and youngest quartile, age
30–64: 10.2±3.7 vs 13.6±1.1; two-way ANOVA, p=0.049)
(Figure 1D). In patients who received mydriatic-assist devices,
or patients using α1 antagonists, the average LOS was longer
(19.4±2.6 minutes vs 15.0±0.6 minutes, p,0.001, and 18.5±2.7
minutes vs 15.1±0.6 minutes, p,0.001, respectively). Interestingly, depending on the surgeon, utilizing the femtosecond
laser either made surgeries quicker (EDD), slower (RJL), or
did not affect the time (GD, JB) (Figure 1E).
Older age was associated with the use of mydriaticassist devices (76.3±2.4 years vs 70.2±0.8 years, Student’s
t-test, p,0.001) and α1 antagonist use (75.4±0.9 years vs
67.4±1.0 years, p,0.001). Patients electing to undergo pretreatment with the femtosecond laser were on average younger than
those who preferred the traditional approach (69.4±1.2 years
vs 71.6±1.1 years, Student’s t-test, p=0.005).
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Complications noted during this study include dislocated
lens with intraocular lens exchange or repositioning, retained
lens fragments, lens fragments in the vitreous, wound leakage, capsular tear (with or without anterior vitrectomy),
macular puckering following surgery, and retinal detachment following surgery. In total, 20 adverse events were
recorded, for a complication rate of 3.1%. The incidence
of complications was not associated with age (Student’s
t-test, p=0.757). Complications were independent of surgeon
(χ2 test, p=0.454), sex (p=0.371), eye (p=0.184), or history or
current use of α1 antagonists (p=0.775). A higher incidence
of complications was noted when mydriatic-assist devices
were used (11.1% vs 2.5%, χ2 test, p=0.001), and a lower
incidence of complications was appreciated when P/K was
used (4.5% vs 1.1%, χ2 test, p=0.018) (Figure 2A and B).
Complications occurred most frequently when mydriaticassist devices were used in conjunction with intracameral
Epi; conversely, complications occurred least frequently
when P/K was administered without a mydriatic-assist device
(χ2, p=0.001) (Figure 2C). There were no hemodynamically
adverse events reported with P/K use intraoperatively.
Patients who had a history of, or were currently using,
α1 antagonists were more likely to require mydriatic-assist
devices (41.5% vs 3.9%, χ2, p,0.001). Patients who underwent pretreatment with the femtosecond laser were less
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Figure 1 (A) Frequency distribution and average LOS in the study population. (B) LOS by all four surgeons (EDD, GD, JB, and RJL). (C) Correlation between patient age and
LOS. (D) The average LOS in different age groups in P/K and Epi groups. (E) The average LOS by each surgeon in femtosecond laser and manual cataract surgery.
Abbreviations: Epi, epinephrine; P/K, phenylephrine/ketorolac; LOS, length of stay.
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Figure 2 (A) Complication rate in eyes with or without mydriatic-assist device use. (B) Complication rate in P/K and Epi groups. (C) Complication rate with or without
mydriatic-assist device use in P/K and Epi groups.
Abbreviations: Epi, epinephrine; P/K, phenylephrine/ketorolac.

likely to require mydriatic-assist devices (3.6% vs 9.6%,
χ2, p=0.003) (Figure 3A). Mydriatic-assist devices were
independent of P/K use (χ2, p=0.306). However, in surgeons
who used mydriatic-assist devices more frequently, the use
of P/K was associated with a reduction in the use of these
devices (χ2, p,0.001) (Figure 3B). The use of P/K was also
associated with a decreased need for mydriatic-assist devices
in patients using α1 antagonists; however, this finding was
not statistically significant due to the sample size (50% vs
28.6%, χ2, p=0.121, n=53) (Figure 3C).
The average preoperative BCVA was 0.50 (±0.03), while
POD 1 and POM 1 UCVA were 0.40 (±0.03) and 0.78 (±0.03)
respectively. There was no statistically significant difference
in POD 1 UCVA or POM 1 BCVA between patients receiving
P/K and those receiving Epi overall (Figure 4A). However,

Clinical Ophthalmology 2018:12

when controlling for age quartile, patients receiving P/K
had significantly better POD 1 UCVA than those receiving
Epi among the older two quartiles (age 69–76, 0.44±0.08 vs
0.38±0.10); age 76–92 (0.34±0.06 vs 0.23±0.08) (two-way
ANOVA, p=0.003) (Figure 4B).
To assess the overall impact of independent variables on
the outcomes of interest, logistic regression models were fit to
adjust for the effect of surgeon, age quartile, sex, use of P/K,
use of femtosecond laser, and α-antagonist use on the rate
of complications and utilization of mydriatic-assist devices.
In the overall sample, older age was associated with an
increased rate of complications (p=0.01203), while use of P/K
was associated with a significantly smaller rate of complications (p=0.0031) compared to Epi. Use of mydriatic-assist
devices varied somewhat by surgeon, and was significantly
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Figure 3 (A) Mydriatic-assist device rate in eyes that underwent femtosecond laser-assisted cataract surgery and manual surgery. (B) Mydriatic-assist device rate by each
surgeon in P/K and Epi groups. (C) Mydriatic-assist device rate in patients with or without history of α1 antagonist use in P/K and Epi groups.
Abbreviations: Epi, epinephrine; P/K, phenylephrine/ketorolac.

lower in patients who underwent femtosecond-assisted laser
procedures.
A linear regression model was fit to evaluate the effect
of surgeon, age quartile, sex, use of femtosecond laser
during surgery, and α-antagonist use on the length of surgical time. Overall, three surgeons (GD, JB, and RJL) all
had significantly longer surgical times compared to EDD
(p,0.05). Older age and use of α-antagonist medication
were also associated with longer surgical times (p=0.0285
and p=0.0033, respectively).

Discussion
A previous study demonstrated the superiority of P/K vs
placebo in maintaining mydriasis and reducing postoperative
pain.14 This single-center, retrospective case study assessed
the perioperative complications, surgical time, and visual
outcomes of intracameral P/K vs Epi in a real-world setting.
All patients received 3 days of preoperative topical NSAID,
which was not given in the FDA trial. In addition, the control
group in our study was administered intracameral Epi, which
was not used in the FDA trial. Given the unique opportunity
to study this drug in a typical practice setting, it was possible
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to analyze outcomes in a real-world treatment setting. Due to
inclusion criteria in this study, patients receiving P/K were
on average 8 years older than the control group receiving
Epi-infused surgical irrigation fluid. Given the propensity for
older individuals to have a positive history for α1-antagonist
use, and the increased likelihood for mydriatric-assist device
placement in older patients, it was surprising to find that
perioperative complications remained fourfold less when the
surgical protocol included P/K. Upon further investigation,
there was a 17-fold increase in complications when mydriaticassist devices were used in conjunction with intracameral Epi
compared to cases with P/K and no mydriatic-assist devices;
however, it should be noted that complications were halved
when P/K was used in conjunction with a mydriatric-assistdevice. It is conceivable that P/K increased overall visibility,
thereby decreasing complication risk.7,16
One can assume that if a Malyugin ring or iris hooks
were used intraoperatively, the surgeon judged the pupil to
be miotic or considered there to be significant risk of miosis
that warranted a pupillary expansion device.7 In the current
study, we found a fourfold increase in complications associated with the use of mydriatic-assist devices. This increase
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Figure 4 (A) UCVA at POD 1 and BCVA at POM 1 in P/K and Epi groups. (B) POD 1 UCVA in different age groups in P/K and Epi groups.
Abbreviations: BCVA, best-corrected visual acuity; Epi, epinephrine; P/K, phenylephrine/ketorolac; POD 1, postoperative day 1; POM 1, postoperative month 1; UCVA,
uncorrected visual acuity.

in complications is thought secondary to the complexity
of these types of cases, which are not uncommon in this
referral group. Supporting this theory, we presented here
that the use of P/K in α1-antagonist patients and the application of femtosecond laser in cataract surgery decreased
the dependence on mydriatic-assist devices (-twofold and
threefold, respectively). Additionally, in surgeons who used
mydriatric-assist devices more frequently than 10% of the
time, the application of P/K was found to decrease the need
for mechanical dilatation.
Overall, there was no detectable difference in visual acuity between patients receiving P/K vs Epi-infused irrigation
solution at POD 1 or POM 1. However, when controlling for
age quartile, there was a significant improvement in POD 1
UCVA in the P/K eyes compared to the Epi eyes among the
older age groups. The immediate improvement in POD 1
visual acuity may be attributed to the anti-inflammatory

Clinical Ophthalmology 2018:12

properties of ketorolac. Furthermore, the LOS was shorter
in three of the four age quartiles when using P/K, independent of femtosecond laser application, which may have also
contributed to the better postoperative results.
This study has several limitations worth noting. First, it
was a single-center study with four surgeons, which may limit
the generalizability of this study to other centers. With four
surgeons, the total treatment effect may be confounded by differing technique or differing patient populations. We showed
that the patient populations differed among surgeons by age,
sex, and use of femtosecond laser. It is not clear whether
these variables influenced the results in any tangible way.
Additionally, it was a retrospective case review looking at a
cohort of patients over a 4-month interval. While retrospective analyses lack the strength of a prospective, randomized
trial, in this real-world setting a retrospective review may in
fact decrease some elements of bias, particularly regarding
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surgeon performance. Therefore, the retrospective nature of
this study best reflects the outcomes that occur in a natural
practice setting. The window of analyzing complications
ranged from 2 months to 1 year depending on the original
date of surgery, which could lead to a lower number of
complications detected among patients with the shortest
follow-up. Patients were selected to receive P/K based on
insurance status, which likely played a role in the older age
in that group, but also may have introduced unintentional
bias between treatment groups beyond the demographic
information captured in Table 1. It is reasonable to suggest,
however, that the older patients in the P/K group may have
had a greater risk for complications, which would in fact
attenuate the treatment effect. It should be noted that in this
study the femtosecond laser was not utilized in patients with
pupils ,5 mm in size. Lastly, because complications were
relatively infrequent, significant results were not always
obtainable from the small sample sizes.

Conclusion
Cataract surgery is a well-established surgical procedure that
provides expeditious functional visual improvement. Over
time, innovation and improvement in existing procedural
techniques along with pharmaceutical advancements have
allowed cataract surgeons to reduce risk, enhance visual
outcomes, and increase patient satisfaction. The addition of
P/K to the surgeon’s regimen has been shown previously
to maintain mydriasis and decrease postoperative pain.14 In
this study, we also showed a decrease in intraoperative and
postoperative complications, a reduction in the need for pupillary dilating devices, decreased age-adjusted surgical time,
and an improvement in POD 1 UCVA in patients $69 years
of age.
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